Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Open
Phase 3
This trial is comparing the targeted cancer drugs ibrutinib and acalabrutinib with, and without, treatment breaks. It is for people with either:
chronic lymphocytic leukaemia (CLL)
small lymphocytic lymphoma (SLL)
It is for people who have already taken:
ibrutinib in the FLAIR trial or the IcICLLe study
ibrutinib as their only treatment on the NHS
ibrutinib or acalabrutinib on the NHS because their CLL or SLL did not go away with their first treatment, or it has come back
Recruitment start: 29 September 2022
Recruitment end: 31 March 2028
Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.
Dr Talha Munir
University of Leeds
University of Leeds Clinical Trials Research Unit
National Institute of Health Research (NIHR) Health Technology Assessment (HTA) Programme
Janssen Pharmaceutica NV
Last reviewed: 15 Sept 2025
CRUK internal database number: 19863
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
